Madrigal Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. (ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany, following European Commission authorization in June 2026. The drug is now listed in the Lauer-Taxe database for prescribing and reimbursement, and can be prescribed once every three months based on clinical symptoms or genetic tests. This launch expansion comes shortly after Arrowhead reported its fiscal Q3 2026 financial results on August 4, with quarterly revenue surging 171% year-over-year to $75.3 million, beating Wall Street expectations of $52.7 million, driven by collaboration income and doubling REDEMPLO U.S. prescription volume. Net loss widened to $194.2 million ($1.36 per share) due to R&D and commercial launch investments, but total cash resources remained strong at $1.56 billion. On August 6, H.C. Wainwright raised its price target on Arrowhead to $120 from $115, reiterating a Buy rating, citing a one-quarter pull-forward in the plozasiran launch timeline for severe hypertriglyceridemia (SHTG) and a new partnership with Madrigal. The bull case is supported by pivotal Phase III efficacy, durable reductions in triglycerides and acute pancreatitis events, and a $1.57 billion cash balance, while the bear case centers on persistent unprofitability, with quarterly operating losses of $170.1 million in Q3, and the commercial ramp remains unproven, with REDEMPLO generating just $2.4 million in early sales. Investors should watch the full presentation of SHASTA data at the ESC Congress on August 30 and the planned sNDA filing for plozasiran before year-end 2026, alongside initial REDEMPLO reimbursement adoption metrics in Germany.

Madrigal Pharmaceuticals has appointed John C. Reed, M.D., Ph.D., to its board of directors. Dr. Reed is Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson and a member of its Executive Committee. Madrigal’s Chairman Julian Baker and CEO Bill Sibold highlighted his track record in advancing innovative medicines and his strategic leadership, which they expect will support the company’s growth and its MASH pipeline, including the launched therapy Rezdiffra.

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals, together with Madrigal Pharmaceuticals, have nominated the first drug candidate under their siRNA collaboration targeting metabolic dysfunction-associated steatohepatitis, or MASH. The milestone triggers the immediate start of IND-enabling studies to support planned clinical trials. The partnership combines Ribo’s siRNA discovery and delivery technology with Madrigal’s clinical expertise in MASH, aiming to develop novel RNA therapeutics for liver diseases with high unmet need. Both companies emphasized the rapid progress made in just a few months and their commitment to advancing the candidate toward clinical development.